CD274 and neoplasm: Based on clinical studies, including KEYNOTE-010, KEYNOTE-024, and CheckMate026, PD-L1 expression level and tumor mutation burden (TMB) are the most commonly used biomarkers 52-54, and the former is frequently used 55.